4 ms·

Petosemtamab (MCLA-158) is an investigational IgG1 antibody targeting EGFR. Merus's other trials (EGFR X c-MET) in NSCLC had serious side effects, but effectiv

• jseliger 2y ago
  Yes: I was in the petosemtamab / MCLA-158 trial at UCSD from Sept. 27 2023 until March 2024, when the tumors in my neck grew by ~20%: http://jakeseliger.com/2024/03/18/in-which-the-squamous-cell-carcinoma-tumors-in-my-neck-grow-by-20-in-two-months/ http://jakeseliger.com/2024/03/18/in-which-the-squamous-cell... from January 2024. Between September and January, however, the tumors in my neck shrank by about 20%, which is a startingly good response by R / M HNSCC standards. Perhaps the most interesting question will ultimately be whether oncologists prescribe petosemtamab for patients who get early clean surgical margins, in an effort to prevent recurrence. Oncologists are reluctant to impose chemo-radiation because of chemo's deleterious side effects, but petosemtamab, though it causes rashes, paronychia, and other skin problems.
• sam537 2y ago
  You should check out a currently approved drug that is very similar called amivantamab (Rybrevant). Also targets EGFR and MET (MET can sometimes be a resistance mechanism to EGFR blockade).